Pharmaceutical companies have committed upwards of $500 billion to US manufacturing and research infrastructure, according to commercial real estate adviser Newmark. Its Q1 2026 report found biomanufacturing employment at a 30-year high, driven by a resurgence in domestic drug production.
The commitments are large and specific. Johnson & Johnson has set out a $55 billion US plan running to early 2029. Roche has committed $50 billion over five years and expects around 12,000 new US jobs. Novartis is investing $23 billion, including new plants, and AbbVie's US programme runs to $100 billion, most recently with $380 million for two new API facilities in North Chicago.
The hiring follows the build
A new plant does not hire all at once. Engineering, commissioning and validation teams arrive first, while the site is still being built. Quality, manufacturing science and technical operations follow as equipment is qualified and processes are transferred. Production staff come last, often in large waves in the months before the first commercial batches.
With so many sites moving through those stages at the same time, the same specialists are in demand everywhere:
- Commissioning, qualification and validation engineers and specialists, including computer system validation.
- MSAT and tech transfer scientists who can move a process from development or another site into a new facility.
- Automation and process engineers for highly automated biologics and sterile operations.
- QA, QC and quality systems professionals to build compliant systems from scratch.
- Aseptic and biologics manufacturing leads and operators for fill-finish and drug substance.
Plan ahead of the curve
Many of these plants come online between 2027 and 2029. Experienced validation, MSAT and quality people will be approached by several new sites at once. Companies that define these roles early, and start searching before construction finishes, will have the strongest choice.
Sources: Pharma Manufacturing, on Newmark's Q1 2026 life science report. Packaging Digest, The Great Pharma Reshoring Wave. Fierce Pharma, AbbVie North Chicago API plants. MarketBeat, Big Pharma US investment.